


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
PFE
Pfizer
$25.49
Strengths

Earnings are forecast to grow

Trading below its fair value

Upgraded on attractively valued

Investors confidence is positive
PFE Price Performance
$25.8 (-1.20%)
$24.52 (+3.96%)
$25.07 (+1.68%)
$26.86 (-5.10%)
PFE has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk

PFE overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Earnings decline YoY

Reported a strong earnings

Revenue increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
PFE Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
PFE Street Sentiment is bullish and have positive views on the near-term outlook
Average key support and resistance price levels
NVS
141.71
+0.13%
SNY
49.06
+1.92%
AZN
94.69
+0.70%
NVO
58.96
+2.87%
MRK
110.59
-0.35%
What is PFE current stock price?
What are PFE stock strengths?
What is PFE Risk Level?
What is PFE market cap and volume?
What is PFE current Stock IQ?
Should I buy PFE stock right now?
Is PFE a Strong Buy right now?
What does a 'Strong Buy' rating mean for PFE?
What does a 'Strong Sell' rating mean for PFE?
What factors influence PFE's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
PFE
Pfizer
Current Price
$25.49
Stock Insights
Strengths

Earnings are forecast to grow

Trading below its fair value

Upgraded on attractively valued

Investors confidence is positive
Linked to PFE
NVS
141.71
+0.13%
SNY
49.06
+1.92%
AZN
94.69
+0.70%
NVO
58.96
+2.87%
MRK
110.59
-0.35%

PFE Price Performance
$25.8 (-1.20%)
$24.52 (+3.96%)
$25.07 (+1.68%)
$26.86 (-5.10%)
PFE Analysts Opinion
PFE Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Earnings decline YoY

Reported a strong earnings

Revenue increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
PFE Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
PFE Street Sentiment is bullish and have positive views on the near-term outlook
PFE has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels
PFE Stock IQ
PFE Latest Analysis
Pfizer inks licensing deal with Madrigal for MASH candidate.
Today
Argobio launches Enodia with €20.7 million seed financing to advance a small molecule platform for targeted protein degradation enabled by proteomics and machine learning. Argobio successfully facilitated fundraising and syndication process following its earlier role in creating and pre-seed funding EnodiaFinancing co-led by Elaia Pfizer Ventures and BpifranceEnodia is the third Argobio-founded company to achieve a seed financing in 2025Paris France – 08 January 2026. Argobio Studio the launch p
Thu Jan 8, 2026
Pfizer Astellas Report Positive Phase 3 Trial Results for PADCEV Combination in Bladder Cancer Treatment.
Thu Jan 8, 2026
Pfizers Stock Just Dropped 6%. Can the Pharmaceutical Giant Bounce Back in 2026?. Key PointsPromising clinical results in 2026 could set the stage for Pfizers stock to rebound.
Thu Jan 8, 2026
This Could Be Key to Pfizers Turnaround in 2026. Key PointsPfizer has been making deals in recent years to enhance its long-term growth potential.
Wed Jan 7, 2026
Pfizer needs more than obesity deal to drive growth post-2028 UBS says.
Wed Jan 7, 2026
Pfizer (PFE) Plans Price Increases on About 80 Medicines Despite Broader Pricing Deals. Pfizer Inc. (NYSE:PFE) is included among the 13 Best January Dividend Stocks to Invest in. Pfizer Inc. (NYSE:PFE) is among the drugmakers planning to raise prices on some medicines starting January 1. The increases will affect about 350 drugs even as President Donald Trump has reached agreements with 14 pharmaceutical companies to lower prices on [….]
Tue Jan 6, 2026
This Flying-Under-the-Radar Pharma Stock Pays Nearly 7% (While Everyones Sleeping). Key PointsThe end of a short-lived COVID-related revenue surge has brought Pfizers stock lower.
Mon Jan 5, 2026
Pfizer (PFE) Navigates Patent Losses With Strategic Cost Controls BMO Capital Reaffirms Outperform Rating.
Fri Jan 2, 2026
Pfizer (PFE) Braces for Bumpy Years as Growth Pushed Out to 2029. Pfizer Inc. (NYSE:PFE) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 16 Pfizer Inc. (NYSE:PFE) said the next few years are expected to be bumpy starting in 2026. The company pointed to lower sales of its COVID vaccine and treatment price cuts promised to the US government and [….]
Tue Dec 30, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.